Humacyte (HUMA) director granted stock options for 80,000 shares at $1.08
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares. The award covers options exercisable for 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036.
The options were granted as compensation and do not reflect an open-market purchase or sale. According to the vesting terms, 25% of the options become exercisable on June 11, 2027, with the remaining options vesting in equal monthly installments through June 11, 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dougan Brady W
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (right to buy) | 0 | $0.00 | -- |
Holdings After Transaction:
Stock Options (right to buy) — 0 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options underlying shares: 80,000 shares
Exercise price: $1.08 per share
Expiration date: June 11, 2036
+3 more
6 metrics
Options underlying shares
80,000 shares
Stock options grant to director
Exercise price
$1.08 per share
Strike price for options
Expiration date
June 11, 2036
Option term end
Initial vesting date
June 11, 2027
First 25% of options vest
Final vesting date
June 11, 2030
Monthly vesting completes
Vesting schedule
1/48 monthly after first 25%
Remaining options vesting pattern
Key Terms
Stock Options (right to buy), exercise price, expiration date, vest
4 terms
Stock Options (right to buy) financial
"security_title: Stock Options (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.0800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What did the Humacyte (HUMA) director receive in this Form 4 filing?
The director received a grant of stock options covering 80,000 Humacyte common shares. These options are a compensation award, not an open-market trade, and give the right to buy shares at a fixed exercise price in the future.
What is the exercise price of the new Humacyte (HUMA) stock options?
The options have an exercise price of $1.08 per share. This means the director can later buy Humacyte common stock at $1.08, regardless of future market price, once the options have vested and before they expire.
When do the Humacyte (HUMA) stock options granted to the director vest?
The first 25% of the options vest on June 11, 2027. The remaining 75% then vest in equal monthly installments, with 1/48 of the award vesting each month until all options are fully vested by June 11, 2030.
When do the newly granted Humacyte (HUMA) stock options expire?
The options expire on June 11, 2036. If the director does not exercise them by that date, they will lapse, and the right to buy Humacyte common shares at $1.08 per share will be lost.